Form 4: Performant Healthcare Director Awarded Restricted Stock Units

Performant Healthcare Inc. Director James LaCamp was granted 35,616 restricted stock units, vesting fully by the 2026 annual meeting or a change in control.

Summary

• James LaCamp, a Director of Performant Healthcare Inc. (PHLT), was awarded 35,616 Restricted Stock Units (RSUs) on July 28, 2025.
• The RSUs were granted at no cost to Mr. LaCamp.
• Each restricted stock unit represents a contingent right to receive one share of PHLT's common stock.
• The units will vest with respect to 100% of the shares subject to the award on the earlier of the Registrant's 2026 annual meeting of stockholders or a Change in Control, as defined in the Registrant's Amended and Restated 2012 Stock Incentive Plan.
• The restricted stock units may be settled only for shares of common stock on a one-for-one basis.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a standard practice for aligning interests and incentivizing performance, indicating routine corporate governance and a positive step for director retention, though it implies future dilution.

Positives

• The equity award aligns the director's financial interests directly with the long-term performance and shareholder value of Performant Healthcare Inc.
• The grant serves as a retention incentive for a key member of the company's leadership.

Negatives

• The future vesting and settlement of these restricted stock units will result in the issuance of new shares, leading to potential dilution for existing shareholders.

Risks

• No new specific risks beyond the inherent nature of equity compensation (e.g., potential future dilution upon vesting) are detailed in this filing.

Future Outlook

The 35,616 Restricted Stock Units granted to Director James LaCamp are scheduled to vest 100% on the earlier of the company's 2026 annual meeting of stockholders or a Change in Control.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across various industries to incentivize and retain key leadership by aligning their interests with shareholder value. It reflects standard corporate governance practices for publicly traded companies.

Comparison to Industry Standards

• This filing details a routine equity compensation grant to a director. While such grants are standard practice across industries for executive and director compensation, the filing itself does not provide specific comparable company data, project benchmarks, or results for direct comparison.

Related Party Transactions

• The grant of Restricted Stock Units to James LaCamp, a Director of Performant Healthcare Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential future dilution from the issuance of common stock upon vesting of the RSUs; increased alignment of the director's interests with shareholder value.
• Employees, customers, suppliers, creditors: No direct impact on these stakeholders is mentioned in this specific filing.

Next Steps

• The Restricted Stock Units will vest on the earlier of the Registrant's 2026 annual meeting of stockholders or a Change in Control.

Key Dates

Recommendation

The Form 4 filing details a routine equity compensation grant to a director, which is a standard practice for aligning management incentives with shareholder interests. This event does not provide new information that would significantly alter the fundamental investment thesis for Performant Healthcare Inc., thus a 'hold' recommendation is appropriate.

Keywords

Performant Healthcare, PHLT, Restricted Stock Units, RSU, Director Compensation, Equity Award, SEC Form 4, Insider Transaction, James LaCamp